FGEN FibroGen, Inc. Stock Quote

Your browser is no longer supported. Please, upgrade your browser.

publish chart | save to portfolio | create alert

FGEN [NASD]

FibroGen, Inc.

Healthcare | Biotechnology | USA

statements

Index	-	P/E	-	EPS (ttm)	-1.32	Insider Own	1.80%	Shs Outstand	88.22M	Perf Week	-0.74%
Market Cap	3.61B	Forward P/E	-	EPS next Y	-1.03	Insider Trans	-2.01%	Shs Float	81.73M	Perf Month	16.85%
Income	-109.90M	PEG	-	EPS next Q	-0.32	Inst Own	73.50%	Short Float	8.06%	Perf Quarter	18.87%
Sales	257.10M	P/S	14.04	EPS this Y	13.60%	Inst Trans	5.24%	Short Ratio	9.00	Perf Half Y	-2.31%
Book/sh	5.20	P/B	8.04	EPS next Y	23.10%	ROA	-12.60%	Target Price	59.25	Perf Year	-7.21%
Cash/sh	6.21	P/C	6.74	EPS next 5Y	-	ROE	-20.00%	52W Range	22.65 - 48.95	Perf YTD	-2.49%
Dividend	-	P/FCF	-	EPS past 5Y	22.50%	ROI	-15.30%	52W High	-14.57%	Beta	1.58
Dividend %	-	Quick Ratio	11.00	Sales past 5Y	13.30%	Gross Margin	99.20%	52W Low	84.64%	ATR	1.79
Employees	531	Current Ratio	11.10	Sales Q/Q	2.10%	Oper. Margin	-47.20%	RSI (14)	55.57	Volatility	3.43% 4.51%
Optionable	Yes	Debt/Eq	0.14	EPS Q/Q	-67.60%	Profit Margin	-42.70%	Rel Volume	0.42	Prev Close	41.91
Shortable	Yes	LT Debt/Eq	0.11	Earnings	May 07 AMC	Payout	-	Avg Volume	731.93K	Price	41.82
Recom	2.00	SMA20	2.79%	SMA50	10.45%	SMA200	6.40%	Volume	304,229	Change	-0.21%

May-01-20

Initiated

Cowen

Market Perform

$40

Apr-27-20

Initiated

BofA/Merrill

Neutral

$45

May-29-19

Resumed

Goldman

Neutral

May-10-19

Downgrade

William Blair

Outperform → Mkt Perform

Apr-12-19

Initiated

Piper Jaffray

Neutral

$65

Feb-11-19

Resumed

Stifel

Buy

$71

Dec-19-18

Upgrade

Citigroup

Neutral → Buy

Aug-08-17

Reiterated

Stifel

Buy

$38 → $80

Aug-08-17

Reiterated

Leerink Partners

Outperform

$52 → $82

Jul-21-17

Downgrade

Goldman

Buy → Neutral

Jul-11-17

Initiated

Jefferies

Buy

Feb-11-16

Upgrade

Credit Suisse

Neutral → Outperform

$40

Jan-21-16

Initiated

Credit Suisse

Neutral

Dec-04-15

Initiated

Citigroup

Buy

Sep-23-15

Initiated

Lake Street

Hold

$25

Jul-29-15

Initiated

Citigroup

Buy

$37

Jul-20-15

Upgrade

Goldman

Neutral → Buy

Dec-09-14

Initiated

Stifel

Buy

$39

Dec-09-14

Initiated

RBC Capital Mkts

Outperform

$38

Jun-24-20 12:00PM	FibroGen Begins Phase II Study for Acute Coronavirus in US Zacks
Jun-23-20 04:05PM	Sarepta Addressing Gene Therapy Issue With Two Acquisitions GuruFocus.com
07:00AM	FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19 GlobeNewswire
Jun-22-20 07:00AM	FibroGen Appoints Thane Wettig as Chief Commercial Officer GlobeNewswire +5.78%
Jun-16-20 09:20AM	Hedge Funds Are Nibbling On FibroGen Inc (FGEN) Insider Monkey
Jun-15-20 10:42AM	Weekly CEO Buys Highlight: Camping World, FibroGen GuruFocus.com
Jun-10-20 08:37PM	FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher Zacks
Jun-09-20 10:17AM	FibroGen Initiates Phase II/III Study in Severe Coronavirus Zacks +6.49%
Jun-08-20 05:00PM	FibroGen Announces New Roxadustat Data Presented at 2020 ERA-EDTA Virtual Congress GlobeNewswire
07:00AM	FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in Italy with Severe COVID-19 GlobeNewswire
May-27-20 07:00AM	FibroGen to Present at Upcoming Investor Conferences GlobeNewswire
May-21-20 07:00AM	European Medicines Agency Accepts Astellas Marketing Authorization Application for Roxadustat GlobeNewswire
May-20-20 10:00PM	European Medicines Agency Accepts Astellas' Marketing Authorization Application for Roxadustat PR Newswire +6.07%
May-11-20 06:32AM	FibroGen, Inc. (NASDAQ:FGEN) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St. +8.76%
May-09-20 05:01PM	FibroGen Inc (FGEN) Q1 2020 Earnings Call Transcript Motley Fool
01:42AM	Edited Transcript of FGEN earnings conference call or presentation 7-May-20 9:00pm GMT Thomson Reuters StreetEvents
May-08-20 07:00AM	FibroGen to Present at Bank of America Securities 2020 Health Care Conference GlobeNewswire
May-07-20 08:40PM	FibroGen (FGEN) Reports Q1 Loss, Lags Revenue Estimates Zacks
04:01PM	FibroGen Reports First Quarter 2020 Financial Results GlobeNewswire
11:24AM	Akebia Shares Climb on Positive Anemia Drug Study Results GuruFocus.com
May-06-20 08:43AM	Why FibroGen (FGEN) Might Surprise This Earnings Season Zacks
May-03-20 10:17AM	How Does Investing In FibroGen, Inc. (NASDAQ:FGEN) Impact The Volatility Of Your Portfolio? Simply Wall St.
Apr-30-20 12:33PM	FibroGen (FGEN) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release Zacks -7.22%
Apr-24-20 07:00AM	FibroGen To Report First Quarter 2020 Financial Results GlobeNewswire
Apr-21-20 05:31PM	Keros Therapeutics Shares Climb 70% After First Post-Covid-19 Biotech IPO GuruFocus.com
Apr-20-20 07:00AM	FibroGen Reports UK Court Ruling GlobeNewswire
Mar-27-20 02:52PM	Hedge Funds Were Selling FibroGen Inc (FGEN) Before The Coronavirus Insider Monkey
Mar-24-20 04:23PM	Biotech stocks have held up better than the broader market and these five are potential winners MarketWatch +12.38%
Mar-04-20 07:07AM	Here's What Analysts Are Forecasting For FibroGen, Inc. After Its Full-Year Results Simply Wall St. +6.21%
Mar-03-20 08:13PM	Edited Transcript of FGEN earnings conference call or presentation 2-Mar-20 10:00pm GMT Thomson Reuters StreetEvents -8.55%
05:50PM	After coronavirus shutdown, S.F. drugmaker reopens China plants in time for major product push American City Business Journals
Mar-02-20 05:15PM	FibroGen (FGEN) Reports Q4 Loss, Lags Revenue Estimates Zacks
04:01PM	FibroGen Reports Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-24-20 12:30PM	Analysts Estimate FibroGen (FGEN) to Report a Decline in Earnings: What to Look Out for Zacks
Feb-18-20 07:00AM	FibroGen to Report Fourth Quarter and Full Year 2019 Financial Results GlobeNewswire
Feb-12-20 09:45AM	FibroGen's (FGEN) NDA for Roxadustat Accepted by the FDA Zacks
09:18AM	The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 05:00PM	FibroGen Announces U.S. FDA Acceptance of New Drug Application for Roxadustat for the Treatment of Anemia of Chronic Kidney Disease GlobeNewswire
08:00AM	FibroGen to Present at 9th Annual SVB Leerink Global Healthcare Conference GlobeNewswire
Feb-03-20 03:42PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
Jan-31-20 09:12AM	FibroGen (NASDAQ:FGEN) Has A Pretty Healthy Balance Sheet Simply Wall St.
Jan-30-20 12:01AM	Astellas Submits Supplemental New Drug Application for Approval of Evrenzo® (roxadustat) for the Treatment of Anemia Associated with Chronic Kidney Disease in Non-Dialysis Dependent Patients in Japan PR Newswire
Jan-13-20 05:59PM	2019 Review: Top Hedge Fund Stocks vs. FibroGen Inc (FGEN) Insider Monkey
Jan-06-20 06:03PM	Four months after CEO's death, biotech company names Lilly vet as leader American City Business Journals
07:00AM	FibroGen Names Enrique Conterno as Chief Executive Officer GlobeNewswire
Dec-24-19 08:55AM	Are Options Traders Betting on a Big Move in FibroGen (FGEN) Stock? Zacks
Dec-23-19 05:42PM	Hemophilia gene therapy leads Bay Area trio of year-end FDA approval requests American City Business Journals
07:00AM	FibroGen Submits New Drug Application to the U.S. FDA for Roxadustat in Patients With Anemia of Chronic Kidney Disease GlobeNewswire
Dec-17-19 06:45AM	Is FibroGen's (NASDAQ:FGEN) 136% Share Price Increase Well Justified? Simply Wall St.
Dec-06-19 10:03AM	Hedge Funds Have Never Been This Bullish On FibroGen Inc (FGEN) Insider Monkey
Dec-02-19 07:00AM	FibroGen Announces Roxadustat Inclusion in Chinas National Reimbursement Drug List GlobeNewswire
Nov-15-19 02:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE +5.75%
Nov-14-19 07:42PM	FIBROGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating FibroGen, Inc. on Behalf of Stockholders and Encourages Investors to Contact the Firm Business Wire
05:24PM	Edited Transcript of FGEN earnings conference call or presentation 11-Nov-19 10:00pm GMT Thomson Reuters StreetEvents
Nov-13-19 08:03PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys, Firm Investigating Possible Securities Fraud GlobeNewswire
07:00PM	Glancy Prongay & Murray LLP Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
06:19PM	INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of FibroGen, Inc. Investors Business Wire
02:00PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE
Nov-11-19 05:15PM	FibroGen (FGEN) Reports Q3 Loss, Tops Revenue Estimates Zacks -14.94%
05:10PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
04:01PM	FibroGen Reports Third Quarter 2019 Financial Results GlobeNewswire
09:21AM	FibroGen (FGEN) Soars: Stock Adds 9.6% in Session Zacks
Nov-08-19 02:10PM	FibroGen Announces Positive Phase 3 Pooled Roxadustat Safety and Efficacy Results for Treatment of Anemia in Chronic Kidney Disease GlobeNewswire +9.61%
01:45PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN ACCESSWIRE
08:14AM	The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut Benzinga
Nov-07-19 04:39PM	FibroGen Presents Phase 3 Efficacy and Safety Results for Roxadustat Versus Epoetin Alfa as Treatment of Anemia in Incident Dialysis Patients with Chronic Kidney Disease GlobeNewswire
Nov-06-19 10:41AM	Mallinckrodt (MNK) Q3 Earnings Beat, Stock Down on Sales Miss Zacks
10:36AM	Jazz Pharma (JAZZ) Q3 Earnings Beat, Xyrem Drives Sales Zacks
09:52AM	Bronstein, Gewirtz & Grossman, LLC Announces Investigation of FibroGen, Inc. (FGEN) ACCESSWIRE
08:52AM	Karyopharm (KPTI) Catches Eye: Stock Jumps 6.4% Zacks
Nov-05-19 10:18PM	HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages FibroGen (FGEN) Investors to Contact Its Attorneys Now, Firm Investigating Possible Securities Fraud PR Newswire +8.00%
05:24PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of FibroGen, Inc. - FGEN GlobeNewswire
11:17AM	Bausch (BHC) Beats on Q3 Earnings & Sales, Raises Guidance Zacks
10:42AM	Endo (ENDP) Q3 Earnings & Revenues Beat Estimates, Down Y/Y Zacks
Nov-04-19 04:38PM	FibroGen, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws GlobeNewswire -7.52%
07:00AM	FibroGen To Report Third Quarter 2019 Financial Results on Monday, November 11, 2019 GlobeNewswire
Oct-31-19 06:53AM	5 Stocks With High Net Income Ratio to Grab Now Zacks
Oct-24-19 12:17PM	Is FibroGen Inc (FGEN) Going To Burn These Hedge Funds ? Insider Monkey
08:17AM	Does Market Volatility Impact FibroGen, Inc.'s (NASDAQ:FGEN) Share Price? Simply Wall St.
Oct-23-19 07:00AM	FibroGen Announces First Patient Dosed in LAPIS, a Phase 3 Clinical Trial of Pamrevlumab for the Treatment of Patients With Locally Advanced Pancreatic Cancer GlobeNewswire
Oct-17-19 11:20AM	Zacks.com featured highlights include: B2Gold, Burlington Stores, FibroGen, Matrix Service Company and Great Lakes Dredge & Dock Zacks
Oct-16-19 08:45AM	5 Stocks With High Net Income Ratio to Scoop Up Zacks
Oct-11-19 10:58AM	Roxadustat Global Phase 3 Results for Treatment of Chronic Kidney Disease (CKD) Anemia to be Presented at American Society of Nephrology Kidney Week 2019 GlobeNewswire
Oct-07-19 05:57PM	FibroGen Congratulates Dr. William G. Kaelin, Jr., Scientific Advisory Board Member, on Receipt of the 2019 Nobel Prize in Physiology or Medicine GlobeNewswire
06:41AM	UK and US scientists win Nobel Medicine Prize Financial Times
Oct-03-19 10:59AM	FibroGen Enters Oversold Territory Zacks
09:42AM	Heron Therapeutics (HRTX) Catches Eye: Stock Jumps 6.2% Zacks
Sep-30-19 08:00PM	FibroGen Receives One of China Pharmaceutical Industrys Highest Awards for Clinical Innovation for Roxadustat GlobeNewswire
07:00AM	FibroGen Announces Publication in the Lancet Respiratory Medicine of Positive Pamrevlumab Efficacy and Safety Data for the Praise Phase 2 Study in Idiopathic Pulmonary Fibrosis GlobeNewswire
Sep-27-19 11:03AM	FibroGen Begins Study on Roxadustat for Chemo-Induced Anemia Zacks
Sep-26-19 11:16AM	Tyme Initiates Pivotal Stage of Pancreatic Cancer Study Zacks
09:00AM	BioLineRx Begins Part 2 of Phase I/IIa Study on Solid Tumors Zacks
07:00AM	FibroGen Announces Initiation of Phase 2 Clinical Trial of Roxadustat for the Treatment of Anemia in Cancer Patients Receiving Chemotherapy GlobeNewswire
Sep-25-19 08:34AM	Dova Pharmaceuticals (DOVA) Jumps: Stock Rises 8.8% Zacks
Sep-23-19 01:20PM	Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa Zacks
12:36PM	Zoetis (ZTS) Receives EC Approval for Simparica Trio in Dogs Zacks
Sep-20-19 11:54AM	FibroGen's Evrenzo Gets Nod in Japan for Anemia with CKD Zacks
03:05AM	Roxadustat Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients GlobeNewswire
03:00AM	Evrenzo® (roxadustat) Tablets Approved in Japan for the Treatment of Anemia Associated with Chronic Kidney Disease in Dialysis Patients PR Newswire
Sep-18-19 08:13AM	Is FibroGen, Inc.'s (NASDAQ:FGEN) 7.6% ROE Worse Than Average? Simply Wall St.

FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. It is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases that is in Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States and Europe; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes. The company is also developing Pamrevlumab, a human monoclonal antibody that inhibits the activity of connective tissue growth factor that is in Phase III clinical development for the treatment of idiopathic pulmonary fibrosis, pancreatic cancer, liver fibrosis, and diabetic kidney disease, as well as Phase II trial for the treatment of Duchenne muscular dystrophy. It has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. The company was incorporated in 1993 and is headquartered in San Francisco, California.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Cotroneo Pat	SVP, Finance and CFO	Jun 16	Sale	39.68	3,928	155,863	271,060	Jun 18 06:35 PM
Conterno Enrique A	Chief Executive Officer	Jun 11	Buy	35.28	19,800	698,599	27,800	Jun 12 06:59 AM
Conterno Enrique A	Chief Executive Officer	Jun 10	Buy	36.29	8,000	290,282	8,000	Jun 12 06:59 AM
Rosenkranz Roberto Pedro	Director	Jun 09	Option Exercise	23.85	24,000	572,400	96,100	Jun 11 09:22 PM
Chung Christine	SVP, China Operations	Mar 19	Option Exercise	25.40	7,345	186,563	166,358	Mar 19 07:55 PM
KEARNS THOMAS F JR	Director	Mar 19	Option Exercise	2.90	18,000	52,200	161,464	Mar 23 05:37 PM
KEARNS THOMAS F JR	Director	Mar 19	Sale	23.17	18,000	417,074	143,464	Mar 23 05:37 PM
Chung Christine	SVP, China Operations	Mar 19	Sale	25.91	7,345	190,282	159,013	Mar 19 07:55 PM
Chung Christine	SVP, China Operations	Mar 18	Option Exercise	25.40	400	10,160	162,918	Mar 19 07:55 PM
Chung Christine	SVP, China Operations	Mar 18	Sale	24.79	3,905	96,799	159,013	Mar 19 07:55 PM
Yu K Peony	Chief Medical Officer	Mar 16	Option Exercise	19.39	3,750	72,713	166,541	Mar 18 08:05 PM
Cotroneo Pat	SVP, Finance and CFO	Mar 16	Sale	26.36	9,239	243,540	236,466	Mar 18 08:00 PM
Chung Christine	SVP, China Operations	Feb 12	Option Exercise	25.40	5,625	142,875	138,269	Feb 13 05:36 PM
Chung Christine	SVP, China Operations	Feb 12	Sale	45.98	5,625	258,617	132,644	Feb 13 05:36 PM
Chung Christine	SVP, China Operations	Feb 11	Option Exercise	25.40	5,625	142,875	138,269	Feb 13 05:36 PM
Chung Christine	SVP, China Operations	Feb 11	Sale	44.48	5,625	250,200	132,644	Feb 13 05:36 PM
Kurkijarvi Kalevi	Director	Feb 10	Option Exercise	18.34	6,000	110,040	34,400	Feb 12 09:52 PM
Kurkijarvi Kalevi	Director	Feb 10	Sale	42.69	6,000	256,140	28,400	Feb 12 09:52 PM
Chung Christine	SVP, China Operations	Jan 07	Option Exercise	25.40	5,625	142,875	138,269	Jan 08 09:12 PM
Chung Christine	SVP, China Operations	Jan 07	Sale	42.76	5,625	240,525	132,644	Jan 08 09:12 PM
Kurkijarvi Kalevi	Director	Jan 06	Option Exercise	18.00	6,000	108,000	34,400	Jan 08 09:14 PM
Chung Christine	SVP, China Operations	Jan 06	Option Exercise	25.40	5,625	142,875	138,269	Jan 08 09:12 PM
Kurkijarvi Kalevi	Director	Jan 06	Sale	42.66	6,000	255,960	28,400	Jan 08 09:14 PM
Chung Christine	SVP, China Operations	Jan 06	Sale	42.98	5,625	241,763	132,644	Jan 08 09:12 PM
Cotroneo Pat	SVP, Finance and CFO	Dec 20	Option Exercise	7.81	56,254	439,427	310,042	Dec 26 04:25 PM
Cotroneo Pat	SVP, Finance and CFO	Dec 20	Sale	45.67	59,456	2,715,517	250,586	Dec 26 04:25 PM
Chung Christine	SVP, China Operations	Dec 17	Option Exercise	25.40	5,625	142,875	138,269	Dec 18 08:33 PM
Chung Christine	SVP, China Operations	Dec 17	Sale	46.98	5,625	264,244	132,644	Dec 18 08:33 PM
Chung Christine	SVP, China Operations	Dec 16	Option Exercise	25.40	2,120	53,848	138,269	Dec 18 08:33 PM
Yu K Peony	Chief Medical Officer	Dec 16	Sale	46.68	3,420	159,646	172,617	Dec 17 08:38 PM
Chung Christine	SVP, China Operations	Dec 16	Sale	47.08	5,625	264,832	132,644	Dec 18 08:33 PM
Kurkijarvi Kalevi	Director	Dec 09	Option Exercise	18.00	6,000	108,000	34,400	Dec 12 06:08 PM
Kurkijarvi Kalevi	Director	Dec 09	Sale	47.50	6,000	285,000	28,400	Dec 12 06:08 PM
Yu K Peony	Chief Medical Officer	Dec 04	Option Exercise	17.46	4,157	72,576	179,397	Dec 06 07:51 PM
Chung Christine	SVP, China Operations	Nov 14	Option Exercise	21.84	5,625	122,838	145,253	Nov 15 06:07 PM
Chung Christine	SVP, China Operations	Nov 14	Sale	34.74	5,625	195,440	139,628	Nov 15 06:07 PM
Chung Christine	SVP, China Operations	Nov 13	Option Exercise	19.39	5,625	109,069	145,253	Nov 15 06:07 PM
Chung Christine	SVP, China Operations	Nov 13	Sale	34.54	5,625	194,288	139,628	Nov 15 06:07 PM
Cotroneo Pat	SVP, Finance and CFO	Nov 08	Option Exercise	2.90	12,500	36,250	256,932	Nov 12 09:15 PM
Kurkijarvi Kalevi	Director	Nov 07	Option Exercise	9.78	6,000	58,650	34,400	Nov 08 06:05 PM
Kurkijarvi Kalevi	Director	Nov 07	Sale	38.27	6,000	229,624	28,400	Nov 08 06:05 PM
Chung Christine	SVP, China Operations	Oct 09	Option Exercise	19.39	5,625	109,069	145,253	Oct 10 07:57 PM
Chung Christine	SVP, China Operations	Oct 09	Sale	36.58	5,625	205,763	139,628	Oct 10 07:57 PM
Chung Christine	SVP, China Operations	Oct 08	Option Exercise	19.39	5,625	109,069	145,253	Oct 10 07:57 PM
Chung Christine	SVP, China Operations	Oct 08	Sale	36.78	5,625	206,914	139,628	Oct 10 07:57 PM
Kurkijarvi Kalevi	Director	Oct 07	Option Exercise	9.78	6,000	58,650	34,400	Oct 09 08:26 PM
Kurkijarvi Kalevi	Director	Oct 07	Sale	36.73	6,000	220,380	28,400	Oct 09 08:26 PM
Chung Christine	SVP, China Operations	Sep 20	Option Exercise	19.39	5,625	109,069	145,253	Sep 23 06:57 PM
Chung Christine	SVP, China Operations	Sep 20	Sale	39.87	5,625	224,269	139,628	Sep 23 06:57 PM
Chung Christine	SVP, China Operations	Sep 19	Option Exercise	19.39	2,120	41,107	145,253	Sep 23 06:57 PM
Chung Christine	SVP, China Operations	Sep 19	Sale	40.45	5,625	227,550	139,628	Sep 23 06:57 PM
Cotroneo Pat	SVP, Finance and CFO	Sep 17	Sale	41.38	3,201	132,457	244,432	Sep 18 07:42 PM
Yu K Peony	Chief Medical Officer	Sep 16	Sale	40.92	3,419	139,905	175,240	Sep 18 07:45 PM
Kurkijarvi Kalevi	Director	Sep 09	Option Exercise	5.95	6,000	35,700	34,400	Sep 10 08:29 PM
Kurkijarvi Kalevi	Director	Sep 09	Sale	40.95	6,000	245,723	28,400	Sep 10 08:29 PM
Chung Christine	SVP, China Operations	Aug 23	Option Exercise	19.39	5,625	109,069	157,195	Aug 26 07:33 PM
Chung Christine	SVP, China Operations	Aug 23	Sale	42.51	5,625	239,099	151,570	Aug 26 07:33 PM
Neff Thomas B	Chief Executive Officer	Aug 22	Option Exercise	2.90	6,834	19,819	2,345,012	Aug 23 04:49 PM
Chung Christine	SVP, China Operations	Aug 22	Option Exercise	19.39	5,625	109,069	157,195	Aug 26 07:33 PM
Chung Christine	SVP, China Operations	Aug 22	Sale	43.84	5,625	246,583	151,570	Aug 26 07:33 PM
Neff Thomas B	Chief Executive Officer	Aug 22	Sale	43.77	1,418	62,066	44,238	Aug 23 04:49 PM
Neff Thomas B	Chief Executive Officer	Aug 22	Sale	43.87	18,400	807,129	2,326,612	Aug 23 04:49 PM
Neff Thomas B	Chief Executive Officer	Aug 21	Option Exercise	2.90	6,834	19,819	2,356,578	Aug 23 04:49 PM
Neff Thomas B	Chief Executive Officer	Aug 21	Sale	44.81	1,418	63,541	45,656	Aug 23 04:49 PM
Neff Thomas B	Chief Executive Officer	Aug 21	Sale	44.79	18,400	824,136	2,338,178	Aug 23 04:49 PM
Neff Thomas B	Chief Executive Officer	Aug 13	Option Exercise	2.90	6,834	19,819	2,368,144	Aug 14 05:38 PM
Neff Thomas B	Chief Executive Officer	Aug 13	Sale	45.61	1,418	64,680	47,074	Aug 14 05:38 PM
Neff Thomas B	Chief Executive Officer	Aug 13	Sale	45.65	18,400	840,006	2,349,744	Aug 14 05:38 PM
Neff Thomas B	Chief Executive Officer	Aug 12	Option Exercise	2.90	6,834	19,819	2,379,710	Aug 14 05:38 PM
Neff Thomas B	Chief Executive Officer	Aug 12	Sale	45.17	1,418	64,056	48,492	Aug 14 05:38 PM
Neff Thomas B	Chief Executive Officer	Aug 12	Sale	45.24	18,400	832,329	2,361,310	Aug 14 05:38 PM
Kurkijarvi Kalevi	Director	Aug 05	Option Exercise	3.50	6,000	21,000	34,400	Aug 07 04:42 PM
Kurkijarvi Kalevi	Director	Aug 05	Sale	45.22	6,000	271,320	28,400	Aug 07 04:42 PM
Neff Thomas B	Chief Executive Officer	Jul 25	Option Exercise	2.90	6,834	19,819	2,391,276	Jul 26 05:31 PM
Neff Thomas B	Chief Executive Officer	Jul 25	Sale	46.88	1,418	66,472	49,910	Jul 26 05:31 PM
Neff Thomas B	Chief Executive Officer	Jul 25	Sale	46.95	18,400	863,858	2,372,876	Jul 26 05:31 PM
Neff Thomas B	Chief Executive Officer	Jul 24	Option Exercise	2.90	6,834	19,819	2,402,842	Jul 26 05:31 PM
Neff Thomas B	Chief Executive Officer	Jul 24	Sale	46.57	1,418	66,036	51,328	Jul 26 05:31 PM
Neff Thomas B	Chief Executive Officer	Jul 24	Sale	46.54	18,400	856,336	2,384,442	Jul 26 05:31 PM
Chung Christine	SVP, China Operations	Jul 11	Option Exercise	28.21	5,625	158,663	157,195	Jul 12 04:23 PM
Neff Thomas B	Chief Executive Officer	Jul 11	Option Exercise	2.90	6,834	19,819	2,414,408	Jul 12 04:27 PM
Neff Thomas B	Chief Executive Officer	Jul 11	Sale	45.09	1,418	63,938	52,746	Jul 12 04:27 PM
Neff Thomas B	Chief Executive Officer	Jul 11	Sale	45.15	18,400	830,836	2,396,008	Jul 12 04:27 PM
Chung Christine	SVP, China Operations	Jul 11	Sale	45.14	5,625	253,915	151,570	Jul 12 04:23 PM
Chung Christine	SVP, China Operations	Jul 10	Option Exercise	29.66	5,625	166,838	157,195	Jul 12 04:23 PM
Neff Thomas B	Chief Executive Officer	Jul 10	Option Exercise	2.90	6,834	19,819	2,425,974	Jul 12 04:27 PM
Neff Thomas B	Chief Executive Officer	Jul 10	Sale	44.81	1,418	63,541	54,164	Jul 12 04:27 PM
Neff Thomas B	Chief Executive Officer	Jul 10	Sale	44.80	18,400	824,300	2,407,574	Jul 12 04:27 PM
Chung Christine	SVP, China Operations	Jul 10	Sale	44.79	5,625	251,953	151,570	Jul 12 04:23 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience